Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Pegasys Market Size Forecast: How Large Could The Market Become By 2030?
The historical expansion was largely driven by the rising incidence of chronic hepatitis infections, the broad use of interferon-based treatments, the well-documented clinical effectiveness of pegylated interferons, the growth of antiviral therapies administered in hospital settings, and the presence of uniform treatment protocols.
The expansion anticipated during the forecast period stems from reduced reliance on direct-acting antivirals, persistent demand among certain patient groups, a heightened emphasis on individualized hepatitis care, broader access initiatives in developing regions, and continued investigation into oncology applications. Key developments shaping this period include a growing shift toward extended-release immunomodulatory treatments, increased adoption of less frequent dosing schedules, greater use of combined antiviral approaches, wider application of pegylation technology in drug design, and improved tracking of therapeutic results.
Download A Free Sample Report For Comprehensive Market Insights:
Pegasys Market Demand Drivers: What Is Fueling Industry Growth?
The increasing occurrence of hepatitis B is expected to drive demand in the pegasys market. Hepatitis B is a viral infection affecting the liver, which can result in chronic illness, cirrhosis, and liver cancer. Its growing prevalence is influenced by factors like higher transmission rates through unprotected sexual contact, intravenous drug use, and insufficient vaccination efforts in various areas. Pegasys is utilized for treating hepatitis B by enhancing immune responses to manage viral replication and minimize liver harm. For example, in April 2024, the European Centre for Disease Prevention and Control, a government health agency in Sweden, reported 28,855 recorded cases of hepatitis B virus (HBV) infection across 30 EU/EEA Member States in 2022, marking a 78% rise compared to 16,187 cases the year prior. Furthermore, the total of 28,420 cases in 2022 corresponds to a crude rate of 8.5 cases per 100,000 population. Consequently, the worldwide increase in hepatitis B prevalence is set to significantly propel growth in the pegasys market.
The growth of the pegasys market is anticipated to be fueled by rising healthcare expenditure. This expenditure involves financial contributions from governments, private entities, and organizations to back medical services, infrastructure, and public health programs. Globally, increasing healthcare spending is propelled by factors like the growing incidence of infectious diseases, the necessity to enhance healthcare systems, and a commitment to better public health results. Higher healthcare spending supports pegasys market expansion by allowing more investment in antiviral drugs, improving patient access to hepatitis treatments, and boosting funding for advanced biologic medications. For instance, in May 2024, the Office for National Statistics, a UK statistical authority, noted that UK healthcare spending reached approximately $359.16 billion (£292 billion) in 2023, with a nominal increase of 5.6% from the previous year. Additionally, total long-term health and social care expenditure saw a real-term rise of 2.8% in 2022. Thus, escalating healthcare expenditure is driving growth in the pegasys market.
Pegasys Market Segmentation Trends And Revenue Drivers
The pegasys market covered in this report is segmented –
1) By Indication: Chronic Hepatitis C, Chronic Hepatitis B
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
3) By End-Users: Hospitals, Clinics, Ambulatory Care, Home Care
Pegasys Market Innovation Trends: Which Developments Are Transforming The Industry?
A notable development in the pegasys market involves broadening its application beyond original uses to address conditions like polycythemia vera (PV) and essential thrombocythemia (ET), thereby strengthening its footprint and accessibility within the oncology and hematology fields. Pegasys is employed in managing PV and ET by aiding in the regulation of irregular blood cell formation, reflecting its extended role in treating myeloproliferative neoplasms. As an illustration, in July 2024, pharmaand GmbH (pharma&), a pharmaceutical enterprise headquartered in Austria, secured endorsement from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for a Type II modification to Pegasys (peginterferon alfa-2a), targeting all indicated patients with PV or ET. Pegasys is presently authorized by the EMA for the management of chronic hepatitis B (CHB) in adults and children aged 3 years and older, as well as chronic hepatitis C (CHC) in adults and children aged 5 years and older, when used alongside other medications. Nevertheless, Pegasys has experienced expanded utilization after its incorporation into independently formulated oncology protocols for myeloproliferative neoplasms (MPNs), PV, and ET.
Pegasys Market Industry Leaders: Which Organizations Are Driving Competition?
Major companies operating in the pegasys market are Roche Holding AG, pharmaand GmbH
Access The Complete Pegasys Market Report:
Pegasys Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the pegasys market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pegasys market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model